vs
Side-by-side financial comparison of KINROSS GOLD CORP (KGC) and Steris (STE). Click either name above to swap in a different company.
KINROSS GOLD CORP is the larger business by last-quarter revenue ($2.5B vs $1.5B, roughly 1.7× Steris).
Kinross Gold Corporation is a Canadian-based gold and silver mining company founded in 1993 and headquartered in Toronto, Ontario, Canada. Kinross currently operates six active gold mines, and was ranked fifth of the "10 Top Gold-mining Companies" of 2019 by InvestingNews. The company's mines are located in Brazil, Mauritania, and the United States. It trades under the KGC ticker in the New York Stock Exchange, and under K in the Toronto Stock Exchange.
Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.
KGC vs STE — Head-to-Head
Income Statement — Q3 FY2023 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $1.5B |
| Net Profit | — | $192.9M |
| Gross Margin | 7.3% | 43.8% |
| Operating Margin | — | 18.3% |
| Net Margin | — | 12.9% |
| Revenue YoY | — | 9.2% |
| Net Profit YoY | — | 11.2% |
| EPS (diluted) | — | $1.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | $192.9M | ||
| Q3 25 | — | $191.9M | ||
| Q2 25 | — | $177.4M | ||
| Q1 25 | — | $145.7M | ||
| Q4 24 | — | $173.5M | ||
| Q3 24 | — | $150.0M | ||
| Q2 24 | — | $145.4M | ||
| Q1 24 | — | $-1.4M |
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 44.2% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 40.2% |
| Q4 25 | — | 18.3% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 17.7% | ||
| Q1 25 | — | 14.6% | ||
| Q4 24 | — | 17.9% | ||
| Q3 24 | — | 16.5% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | 22.0% |
| Q4 25 | — | 12.9% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 12.8% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | 11.3% | ||
| Q2 24 | — | 11.4% | ||
| Q1 24 | — | -0.1% |
| Q4 25 | — | $1.96 | ||
| Q3 25 | — | $1.94 | ||
| Q2 25 | — | $1.79 | ||
| Q1 25 | — | $1.48 | ||
| Q4 24 | — | $1.75 | ||
| Q3 24 | — | $1.51 | ||
| Q2 24 | — | $1.46 | ||
| Q1 24 | — | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.1M | $423.7M |
| Total DebtLower is stronger | $751.5M | $1.9B |
| Stockholders' EquityBook value | — | $7.2B |
| Total Assets | $10.4B | $10.6B |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $423.7M | ||
| Q3 25 | — | $319.2M | ||
| Q2 25 | — | $279.7M | ||
| Q1 25 | — | $171.7M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $172.2M | ||
| Q2 24 | — | $198.3M | ||
| Q1 24 | — | $207.0M |
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $3.1B |
| Q4 25 | — | $7.2B | ||
| Q3 25 | — | $7.0B | ||
| Q2 25 | — | $7.0B | ||
| Q1 25 | — | $6.6B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.6B | ||
| Q2 24 | — | $6.4B | ||
| Q1 24 | — | $6.3B |
| Q4 25 | — | $10.6B | ||
| Q3 25 | — | $10.4B | ||
| Q2 25 | — | $10.4B | ||
| Q1 25 | — | $10.1B | ||
| Q4 24 | — | $10.0B | ||
| Q3 24 | — | $10.2B | ||
| Q2 24 | — | $10.1B | ||
| Q1 24 | — | $11.1B |
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $649.0M | $298.2M |
| Free Cash FlowOCF − Capex | — | $199.5M |
| FCF MarginFCF / Revenue | — | 13.3% |
| Capex IntensityCapex / Revenue | — | 6.6% |
| Cash ConversionOCF / Net Profit | — | 1.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $917.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $298.2M | ||
| Q3 25 | — | $287.8M | ||
| Q2 25 | — | $420.0M | ||
| Q1 25 | — | $260.8M | ||
| Q4 24 | — | $332.8M | ||
| Q3 24 | — | $250.7M | ||
| Q2 24 | — | $303.7M | ||
| Q1 24 | — | $254.8M |
| Q4 25 | — | $199.5M | ||
| Q3 25 | — | $201.3M | ||
| Q2 25 | — | $326.4M | ||
| Q1 25 | — | $189.9M | ||
| Q4 24 | — | $243.6M | ||
| Q3 24 | — | $148.8M | ||
| Q2 24 | — | $195.7M | ||
| Q1 24 | — | $163.3M |
| Q4 25 | — | 13.3% | ||
| Q3 25 | — | 13.8% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | — | 11.2% | ||
| Q2 24 | — | 15.3% | ||
| Q1 24 | — | 14.6% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 7.7% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | — | 1.55× | ||
| Q3 25 | — | 1.50× | ||
| Q2 25 | — | 2.37× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KGC
Segment breakdown not available.
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
